Carey Anders

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer
    Carey K Anders
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e61359. 2013
  2. pmc The management of early-stage and metastatic triple-negative breast cancer: a review
    Carey K Anders
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
    Hematol Oncol Clin North Am 27:737-49, viii. 2013
  3. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
  4. pmc Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer
    Carey K Anders
    University of North Carolina, Chapel Hill, 27517, USA
    Clin Cancer Res 16:4702-10. 2010
  5. doi request reprint The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
    Carey K Anders
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Cancer 117:1602-11. 2011
  6. pmc An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
    Andrea H Bild
    Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
    Breast Cancer Res 11:R55. 2009
  7. pmc Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
    J Chuck Harrell
    Lineberger Comprehensive Cancer Center, University of North Carolina, 450 West Drive, CB7295, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 132:523-35. 2012
  8. pmc Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
  9. pmc Understanding and treating triple-negative breast cancer
    Carey Anders
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncology (Williston Park) 22:1233-9; discussion 1239-40, 1243. 2008

Collaborators

Detail Information

Publications9

  1. pmc Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer
    Carey K Anders
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e61359. 2013
    ..We compared pharmacokinetics (PK) and efficacy of PEGylated liposomal doxorubicin (PLD) with non-liposomal doxorubicin (NonL-doxo) in an intracranial model of BC...
  2. pmc The management of early-stage and metastatic triple-negative breast cancer: a review
    Carey K Anders
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
    Hematol Oncol Clin North Am 27:737-49, viii. 2013
    ..The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC. ..
  3. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
    ..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs...
  4. pmc Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer
    Carey K Anders
    University of North Carolina, Chapel Hill, 27517, USA
    Clin Cancer Res 16:4702-10. 2010
    ....
  5. doi request reprint The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
    Carey K Anders
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Cancer 117:1602-11. 2011
    ..In a single-institution cohort study, the authors attempted to determine whether the inferior outcome noted with TNBC brain metastases is more reflective of a higher risk population or the subtype itself...
  6. pmc An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
    Andrea H Bild
    Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
    Breast Cancer Res 11:R55. 2009
    ..Additional work has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as well as to suggest therapeutic opportunities linked to pathway activation...
  7. pmc Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse
    J Chuck Harrell
    Lineberger Comprehensive Cancer Center, University of North Carolina, 450 West Drive, CB7295, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 132:523-35. 2012
    ..In total, these data identify that depending upon the organ of relapse, a combination of gene expression signatures most accurately predicts metastatic behavior...
  8. pmc Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
    ..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
  9. pmc Understanding and treating triple-negative breast cancer
    Carey Anders
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncology (Williston Park) 22:1233-9; discussion 1239-40, 1243. 2008
    ....